Bayer wins court ruling against Pfizer, Moderna in mRNA patent case
by@Reuters
Summary
A federal judge in Delaware has rejected attempts by Pfizer, BioNTech, and Moderna to dismiss patent infringement lawsuits filed by Bayer, specifically concerning messenger RNA technology used in their COVID-19 vaccines. Bayer claims that the companies used patented innovations developed by its Monsanto unit in the 1980s without authorization. This ruling allows Bayer's claims, which originate from research aimed at stabilizing mRNA for agricultural applications, to proceed in court. Bayer expressed satisfaction with the decision, while the vaccine makers contended that their technology differs from Bayer's patented processes.
Tokens
$PFE$MRNA$BAYGn
Analysis
Bayer: Bayer is a global life sciences company whose Monsanto agricultural unit holds patents on mRNA-related innovations originally developed for crop applications. Bayer filed the suit in January and expressed satisfaction with the judge's decision rejecting the defendants' dismissal requests. Pfizer: Pfizer is a major pharmaceutical company that co-developed one of the primary mRNA-based COVID-19 vaccines. In this case, a Delaware federal judge rejected its early-stage motion to dismiss Bayer's patent infringement claims over mRNA stabilization technology allegedly derived from Monsanto's earlier work. Moderna: Moderna is a biotechnology company focused on mRNA therapeutics and vaccines, including its COVID-19 shot. The court denied its bid to dismiss the lawsuit, allowing Bayer's claims regarding unauthorized use of patented mRNA technology to proceed. BioNTech: BioNTech is a German biotechnology firm that partnered with Pfizer to develop and commercialize an mRNA COVID-19 vaccine. It is a co-defendant in the Bayer patent case, where its request to dismiss the claims was also rejected by the Delaware court. Monsanto: Monsanto, now a Bayer subsidiary, is an agricultural biotechnology company whose 1980s innovations in mRNA stabilization for crops form the basis of the asserted patents. Bayer is pursuing the lawsuit through its CropScience unit on behalf of these intellectual property rights. Sara Horton: Sara Horton is an attorney at Willkie Farr & Gallagher representing Pfizer in the ongoing mRNA patent dispute with Bayer. The firm is defending against claims of unauthorized use of the patented technology. Daryl Wiesen: Daryl Wiesen is an attorney at Goodwin Procter representing Moderna in the Delaware patent suit. He advanced arguments including that the patent covered unpatentable subject matter. Martina Hufnal: Martina Hufnal is an attorney at Fish & Richardson representing BioNTech in the Bayer-initiated patent case. She is part of the legal team responding to the infringement allegations. Michael Wilson: Michael Wilson is an attorney at Munck Wilson Mandala representing Bayer in the patent litigation. He is handling the case asserting infringement of Monsanto-developed mRNA technology. William Bryson: William Bryson is a US Circuit Judge sitting by designation in the US District Court for the District of Delaware. He ruled that the vaccine makers failed to demonstrate at an early stage that Bayer's patent was invalid or not infringed. Case Status: The lawsuits remain active in Delaware federal court with Bayer expressing confidence in its position following the ruling. Court Ruling: A federal judge rejected early dismissal motions, allowing Bayer's patent infringement claims over mRNA technology to advance against the vaccine makers. Technology Origin: The asserted patents stem from Monsanto's earlier research on mRNA stabilization techniques developed for agricultural applications.
Categories
macropolitics